Together, these analyses again suggest that although the IGF-1 system clearly plays a role in ES tumor biology, neither high ligand availability nor high receptor number is consistently defined as a predominant driving factor for poor patient outcomes. This evidence concerns the gene IGF1 and neoplasm.